Loading stock data…
IMNN
$2.80-0.03 (-1.06%)
Market ClosedLast close May 1
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Imunon, Inc. in the Healthcare sector is trading at $2.80. The stock is currently near its 52-week low of $2.52, remaining 35.8% below its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why IMNN maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.80
Potential Upside
5%
Whystock Fair Value$2.94
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Mean target$19.20+585.7%
Range$10.00 – $33.00
Fundamentals
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II cli...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-205.26%
Volume
Today's trading volume
12,917
Recent News
Imunon, Inc. Q4 2025 Earnings Call Summary
Moby summary of Imunon, Inc.'s Q4 2025 earnings call
Imunon Inc (IMNN) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Management
Imunon Inc (IMNN) extends its operating runway and reports promising clinical trial progress amidst financial challenges.
Imunon Inc (IMNN) Q3 2025 Earnings Call Highlights: Promising Advances in Immunotherapy and ...
Imunon Inc (IMNN) reports significant progress in its pivotal phase 3 trial for ovarian cancer, while navigating financial challenges and market conditions.
Imunon (IMNN) Q3 2025 Earnings Call Transcript
Stacy Lindborg: Thank an you, Peter, and good morning, everyone. Joining me on the call this morning is Dr. Douglas Faller, our Chief Medical Officer, and Ms. Kim Graper, our Interim Chief Financial Officer, who will be reviewing our financial results for the third quarter of 2025. Mr. Michael Tardugno, the Executive Chairman of our board, and Dr. Khursheed Anwer, our Chief Scientific Officer, are also on the line and will be available for Q&A. We continue to make meaningful progress with our proprietary IL-12 immunotherapy, IMNN-001, through the OVATION 3 pivotal phase III trial for newly diagnosed advanced ovarian cancer.
Imunon Inc (IMNN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Imunon Inc (IMNN) reports significant progress in ovarian cancer treatment trials while navigating a tough capital market environment.